| 摘要 |
FIELD: medicine.SUBSTANCE: invention refers to medicine, particularly to laboratory diagnostics of kidney diseases, and is applicable for patient examination to diagnose incipient and further stages of chronic kidney disease. Patient's blood is analysed to measure lipocalin-2 in ng/ml and urea in mmole/l; lipocalin-2/urea ratio is derived; if the calculated ratio is 2.51-2.90, the first stage of chronic kidney disease is diagnosed; the value falling within the range of 2.91-3.50 relates to the second stage of chronic kidney disease; if the value is from 3.51 to 3.80, the patient is diagnosed with the stage 3A of chronic kidney disease; the range from 3.81 to 4.00 enables diagnosing the stage 3B of chronic kidney disease; if the value ranges from 4.01-4.50, the fourth stage of chronic kidney disease is diagnosed in the patient; the fifth terminal stage of chronic kidney disease is diagnosed if the ratio is >4.51. The authors of the invention have been the first to determine normal NGAL/urea ratios in healthy people. They make 1.20-2.50. The method enables diagnosing the stages of chronic kidney disease with using the analysis of blood serum NGAL concentration and NGAL/urea ratio. In contrast to currently existing approaches, the technique enables diagnosing the CKD stages more accurately, as well as avoiding additional blood sampling and invasive diagnostic techniques.EFFECT: presented technique is quantitative, and so accurate and objective; its advantage is quickness and ease of implementation, absence of necessity to use expensive equipment, radiopharmaceuticals, and possibility to perform in the outpatient setting.3 tbl, 2 ex |
